KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation and Depletion: 2018-2024

Historic Depreciation and Depletion for Aquestive Therapeutics (AQST) over the last 7 years, with Dec 2024 value amounting to $640,000.

  • Aquestive Therapeutics' Depreciation and Depletion fell 12.58% to $139,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $565,000, marking a year-over-year decrease of 36.16%. This contributed to the annual value of $640,000 for FY2024, which is 44.49% down from last year.
  • As of FY2024, Aquestive Therapeutics' Depreciation and Depletion stood at $640,000, which was down 44.49% from $1.2 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Depreciation and Depletion ranged from a high of $3.4 million in FY2020 and a low of $640,000 during FY2024.
  • For the 3-year period, Aquestive Therapeutics' Depreciation and Depletion averaged around $1.4 million, with its median value being $1.2 million (2023).
  • Per our database at Business Quant, Aquestive Therapeutics' Depreciation and Depletion climbed by 18.85% in 2020 and then crashed by 49.21% in 2023.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Depreciation and Depletion stood at $3.4 million in 2020, then decreased by 14.15% to $2.9 million in 2021, then declined by 22.05% to $2.3 million in 2022, then slumped by 49.21% to $1.2 million in 2023, then plummeted by 44.49% to $640,000 in 2024.